

# Amy K Darke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7095281/publications.pdf>

Version: 2024-02-01

33  
papers

5,038  
citations

430874

18  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

6462  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers. JAMA - Journal of the American Medical Association, 2009, 301, 39.	7.4	1,832
2	Vitamin E and the Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1549.	7.4	1,458
3	Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. Journal of the National Cancer Institute, 2013, 105, 1132-1141.	6.3	263
4	Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, 99, 1375-1383.	6.3	248
5	Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. Journal of the National Cancer Institute, 2014, 106, djt456.	6.3	221
6	Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADVISE). JAMA Neurology, 2017, 74, 567.	9.0	215
7	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 167.	7.4	202
8	Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention. Cancer Prevention Research, 2008, 1, 167-173.	1.5	92
9	Longitudinal Analysis of Sexual Function Reported by Men in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, 99, 1025-1035.	6.3	80
10	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1050-1058.	2.5	55
11	Finasteride Decreases the Risk of Prostatic Intraepithelial Neoplasia. Journal of Urology, 2007, 178, 107-110.	0.4	52
12	Long-Term Effects of Finasteride on Prostate Cancer Mortality. New England Journal of Medicine, 2019, 380, 393-394.	27.0	44
13	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. JAMA Ophthalmology, 2015, 133, 17.	2.5	38
14	Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncology, 2021, 7, 246.	7.1	34
15	Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention. Cancer Prevention Research, 2017, 10, 45-54.	1.5	32
16	Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). Journal of the National Cancer Institute, 2018, 110, 734-742.	6.3	32
17	S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients. Journal of the National Cancer Institute, 2022, 114, 372-380.	6.3	28
18	A Functional Variant in <i>NKX3.1</i> Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prevention Research, 2014, 7, 950-957.	1.5	22

#	ARTICLE	IF	CITATIONS
19	Non-steroidal anti-inflammatory drug (<sc>NSAID</sc>) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial. <i>BJU International</i> , 2016, 117, 500-506.	2.5	18
20	Moving a randomized clinical trial into an observational cohort. <i>Clinical Trials</i> , 2013, 10, 131-142.	1.6	17
21	Health-Related Quality-of-Life Findings for the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1373-1385.	6.3	11
22	Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials. <i>JCO Oncology Practice</i> , 2021, 17, e1246-e1257.	2.9	8
23	Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7010-7010.	1.6	8
24	Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. <i>Biostatistics</i> , 2010, 11, 413-418.	1.5	6
25	Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. <i>Supportive Care in Cancer</i> , 2017, 25, 1191-1199.	2.2	5
26	Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials. <i>JCO Oncology Practice</i> , 2022, 18, e442-e451.	2.9	5
27	Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. <i>Contemporary Clinical Trials</i> , 2020, 95, 106037.	1.8	4
28	Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases: SWOG S0702, NCT00874211.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11502-11502.	1.6	4
29	Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. <i>Trials</i> , 2016, 17, 400.	1.6	2
30	Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B). <i>Acta Ophthalmologica</i> , 2021, 99, e285-e287.	1.1	1
31	Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6652-TPS6652.	1.6	1
32	Response to H. Nabi et al.. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1424-1425.	6.3	0
33	Feasibility of a digital medicine program in optimizing opioid pain control in cancer patients (SWOG) Tj ETQq1 1 0.784314 rgBT /Overbor	1.6	0